Prospects of glutamate antagonists in the therapy of Parkinson's disease

Fundamental and Clinical Pharmacology

Volumn 12, Issue 1, 1998, Pages 4-12

  Blandini, F ^a   Greenamyre, J T ^b  

^a C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Basal ganglia; Excitotoxicity; Glutamate; NMDA; Parkinson's disease

Indexed keywords

6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; GLUTAMATE RECEPTOR ANTAGONIST; GLUTAMIC ACID; LEVODOPA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; REMACEMIDE;

BASAL GANGLION; DOPAMINERGIC NERVE CELL; HUMAN; NERVE PROJECTION; NEUROTOXICITY; NEUROTRANSMISSION; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

EID: 0031950985     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1472-8206.1998.tb00918.x     Document Type: Review

References (91)

1. Albin RL, Greenamyre JT. Alternative excitotoxic hypotheses. Neurology 1992 ; 42 : 733-8
2. Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci 1989 ; 12 : 366-75
3. Albin RL, Makowiec RL, Hollingsworth Z, Dure LS, Penney JB, Young AB. Excitatory amino acid binding sites in the basal ganglia of the rat: a quantitative autoradiographic study. Neuroscience 1992 ; 46 : 35-48
4. Albin RL, Young AB, Penney JB, The functional anatomy of disorders of the basal ganglia. Trends Neurosci 1995 ; 18 : 63-4
5. Alexander GE, Crutcher MD. Functional architecture of basal ganglia circuits: neural substrates of parallel processing. Trends Neurosci 1990 ; 13 : 266-71
6. Anderson JJ, Kuo S, Chase TN. Endogenous excitatory amino acids tonically stimulate striatal acetylcholine release through NMDA but not AMPA receptors. Neurosci Lett 1994 ; 176 : 264-8
7. Beal MF, Swartz KJ, Hyman BT, Storey E, Finn SF, Koroshetz W. Aminoxyacetic acid results in excitotoxin lesions by a novel indirect mechanism. J Neurochem 1991 ; 57 : 1068-73
8. Beal MF, Hyman BT, Koroshetz W. Do defects in mitochondrial energy metabolism underlie the pathology of neurodegenerative diseases? Trends Neurosci 1993 ; 16 : 125-31
9. Benveniste M, Mayer ML. Multiple effect of spermine on N-methyl-D-aspartate receptor responses of rat cultured hippocampal neurones. J Physiol (Lond) 1993 ; 464 : 131-63
10. Bergman H, Wichmann T, DcLong MR. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 1990 ; 249 : 1436-8
11. Bettler B, Mulle C. Neurotransmitter receptors II. AMPA and kainate receptors. Neuropharmacology 1995 ; 34 : 123-39
12. Blandini F, Greenamyre JT. Effect of subthalamic nucleus lesion on mitochondrial enzyme activity in rat basal ganglia. Brain Res 1995 ; 669 : 59-66
13. Blandini F, Porter RHP, Greenamyre JT. Autoradiographic study of mitochondrial complex I and glutamate receptors in the basal ganglia of rats after unilateral subthalamic lesion. Neurosci Lett 1995 ; 186 : 99-102
14. Bliss TV, Collingridge GL. A synaptic model of memory: long-term potentiation in the hippocampus. Nature 1993 ; 361 : 31-9
15. 14C]GABA uptake in the basal ganglia of rats following lesions in the subthalamic region suggest a role for excitatory amino acid but not GABA-mediated transmission in subthalamic nucleus efferents. Exp Neurol 1991 ; 113 : 171-81
16. Brotchie JM, Mitchell IJ, Sambrook MA, Crossman AR. Alleviation of parkinsonism by antagonism of excitatory amino acid transmission in the medial segment of the globus pallidus in rat and primate. Mov Disord 1991 ; 6 : 133-8
17. Calabresi P, Mercuri NB, Sancessario G, Bernardi G. Electrophysiology of dopamine-denervated striatal neurons. Implications for Parkinson's disease. Brain 1993 ; 116 : 433-52
18. Calabresi P, Pisani A, Mercuri NB, Bernardi G. The corticostriatal projection: from synaptic plasticity to dysfunctions of the basal ganglia. Trends Neurosci 1996 ; 19 : 19-24
19. Chesselet MF, Delfs JM. Basal ganglia and movement disorders: an update. Trends Neurosci 1996 ; 19 : 417-22
20. Chiba K, Trevor AJ, Castagnoli N Jr. Metabolism of the neurotoxic tertiary amine, MPTP. by brain monoamine oxidase. Biochem Biophys Res Commun 1984 ; 120 : 574-8
21. Collingridge GL, Singer W. Excitatory amino acid receptors and synaptic plasticity. Trends Pharmacol Sci 1990 ; 11 : 290-6
22. DeLong MR. Primate models of movement disorders of basal ganglia origin. Trends Neurosci 1990 ; 13 : 281-5
23. Ehringer H, Hornykiewicz O. Verteilung von noradrenalin und dopamin (3-hydroxytyramin) im gehirn des menschen und ihr verhalten bei erkrankungen des extrapyramidalen systems. Klin Wochenschr 1960 ; 38 : 1236-9
24. +, and adenosine triphosphate in isolated brain synaptosomes. J Gen Physiol 1990 ; 95 : 591-616
25. Gerfen CR. The neostriatal mosaic: multiple levels of compartmental organization. Trends Neurosci 1992 ; 15 : 133-9
26. Graybiel AM. Neurotransmitters and neuromodulators in the basal ganglia. Trends Neurosci 1990 ; 13 : 244-54
27. Greenamyre JT. Glutamate-dopamine interactions in the basal ganglia: relationship to Parkinson's disease. J Neural Transm 1993 ; 91 : 255-69
28. Greenamyre JT, Porter RHP. Anatomy and physiology of glutamate in the CNS. Neurology 1994 ; 44 : S7-13
29. Greenamyre JT, Eller RV, Zhang Z, Ovadia A, Kurlan R, Gash DM. Antiparkinsonian effects of remacemide, a glutamate antagonist, in rodent and primate models of Parkinson's disease. Ann Neural 1994 ; 35 : 655-61
30. Greene JG, Greenamyre JT. Characterization of the excito-toxic potential of the reversible succinate dehydrogenase inhibitor malonate. J Neurochem 1995 ; 64 : 430-6
31. Greene JG, Porter RHP, Eller RV, Greenamyre JT. Inhibition of succinate dehydrogenase by malonic acid produces an 'excitotoxic' lesion in rat striatum. J Neurochem 1993 ; 61 : 1151-4
32. Hamada I, DeLong MR. Effects of subthalamic nucleus lesions on pallidal discharge in the primate. Biomed Res 1993 ; 14 : 43-5
33. Hassani OK, Mouroux M, Feger J. Increased subthalamic neuronal activity after nigral dopaminergic lesion independent of disinhibition via the globus pallidus. Neuroscience 1996 ; 72 : 105-15
34. Janetzky B, Hauck S, Youdim MBH, Riederer P, Jellinger K, Pantucek F et al. Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's disease. Neurosci Lett 1994 ; 169 : 126-8
35. Kaatz KW, Albin RL. Intrastriatal and intrasubthalamic stimulation of metabotropic glutamate receptors: a behavioral and fos immunoistochemical study. Neuroscience 1995 ; 66 : 55-65
36. Klockgether T, Turski L. NMDA antagonists potentiate antiparkinsonian actions of L-dopa in monoamine-depleted rats. Ann Neurol 1990 ; 28 : 536-9
37. Klockgether T, Turski L, Honore T, Zhang Z, Gash DM, Kurlan R et al. The AMPA receptor antagonist NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys. Ann Neurol 1991 ; 30 : 717-23
38. Klockgether T, Jacobsen P, Löschmann PA, Turski L. The antiparkinsonian agent budipine is an N-methyl-D-aspartate antagonist. J Neural Transm [Park Dis-Dement Sect] 1993 ; 5 : 101-6
39. Kornhuber J, Bormann J, Retz W, Hubers M, Riederer P. Memantine displaces [3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex. Eur J Pharmacol 1989 ; 166: 589-90
40. Kornhuber J, Bormann J, Hubers M, Rusche K, Riederer P. Effects of the 1-amino-adamantines at the MK-801-binding site of the NMDA-receptor-gatcd ion channel: a human postmortem brain study. Eur J Pharmacol 1991 ; 206 : 297-300
41. Krige D, Carroll MT, Cooper JM, Marsden CD, Schapira AHV. Platelet mitochondrial function in Parkinson's disease. Ann Neurol 1992 ; 32 : 782-8
42. Kure S, Tominaga T, Yoshimoto T. Tada K, Narisawa K. Glutamate triggers internucleosomal DNA cleavage in neuronal cells. Biochem Biophys Res Commun 1991 ; 179 : 39-45
43. Landwehrmeyer GB, Standaert DG, Testa CM, Penney JB, Young AB. NMDA receptor subunit mRNA expression by projection neurons and interneurons in rat striatum. J Neurosci 1995 ; 15 : 5297-307
44. Limousin P, Pollak P, Benazzouz A, Lebas JF, Broussole E, Perret JE et al. Effect on parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet 1995 ; 345 : 91-5
45. Löschmann PA, Lange KA, Kunow M, Rettig KJ, Jähnig P, Honoré T et al. Synergism of the AMPA-antagonist NBQX and the NMDA-antagonist CPP with L-Dopa in models of Parkinson's disease. J Neural Transm [Park Dis-Dement Sect] 1991 ; 3 : 203-13
46. Marey-Semper I, Gelman M, Lévi-Strauss M. A selective toxicity toward cultured mesencephalic dopaminergic neurons is induced by the synergistic effects of energetic metabolism impairment and NMDA receptor activation. J Neurosci 1995 ; 15 : 5912-8
47. Markey SP, Johannessen JN, Chiueh CC, Burns RS, Herkenham MA. Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism. Nature 1984 ; 311 : 464-7
48. McBain CJ, Mayer L. N-methyl-D-aspartic acid receptor structure and function. Physiol Rev 1994 ; 74 : 723-60
49. Meldrum B, Garthwaite J. Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmacol Sci 1990 ; 11 : 379-87
50. Miller WC, DeLong MR. Altered tonic activity of neurons in the globus pallidus and subthalamic nucleus in the primate MPTP model of parkinsonism. In: Carpenter MB, Jayrman A, eds. The Basal Ganglia II. New York: Plenum Press; 1987. p 415-27
51. Mitchell IJ, Clarke CE, Boyce S, Robertson RG, Peggs DE, Sambrook MA et al. Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-1,2,3,6-tetrahydropyridine. Neuroscience 1989 ; 32 : 226-31
52. Mizuno Y, Suzuki K, Ohta S. Postmortem changes in mitochondrial respiratory enzymes in brain and a preliminary observation in Parkinson's disease. J Neurol Sci 1990 ; 96 : 49-57
53. Montastruc JL, Rascol O, Senard JM. New directions in the drug treatment of Parkinson's disease. Drugs Aging 1996 ; 9 : 169-84
54. 2-mediated behavior in the 6-hydroxydopamine model of turning: relationship with c-fos expression. J Pharmacol Exp Ther 1992 ; 260 : 402-8
55. Morelli M, Pinna A, Fenu S, Carta A, Cozzolino A, Di Chiara G. Differential effects of MK 801 and scopolamine on c-fos expression induced by L-dopa on the striatum of 6-hydroxydopamine lesioned rats. Synapse 1994 ; 18 : 288-93
56. Nicklas WJ, Vyas I, Heikkila RE. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenylpyride, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropiridine. Life Sci 1985 ; 36 : 2503-8
57. Nicoletti F, Bruno V, Copani A, Casabona G, Knöpfel T. Metabotropic glutamate receptors: a new target for the therapy of neurodegenerative disorders? Trends Neurosci 1996 ; 19 : 267-71
58. Novelli A, Reilly JA, Lysko PG, Henneberry RC. Glutamate becomes neurotoxic via the NMDA receptor when intracellular energy levels are reduced. Brain Res 1988 ; 451 : 205-12
59. Olney JW, Ho OL, Rhee V. Cytotoxic effects of acidic amino acids on the infant mouse central nervous system. Exp Brain Res 1971 ; 14 : 61-76
60. Orrenius S, Nicotera P. The calcium ion and cell death. J Neural Transm 1994 ; 43 : S1-11
61. Pupa SM, Chase TN. Levodopa-induced dyskinesis improved by a glutamate antagonist in parkinsonian monkeys. Ann Neurol 1996 ; 39 : 574-8
62. Papa SM, Boldry RC, Engber TM, Kask AM, Chase TN. Reversal of levodopa-induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade Brain Res 1995 ; 701 : 13-8
63. Parent A, Hazrati LN. Functional anatomy of the basal ganglia. II. The place of subthalamic nucleus and external pallidum in basal ganglia circuitry, Brain Res Rev 1995 ; 20 : 128-54
64. Parker WD, Boyson SJ, Parks JK. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol 1989 ; 26 : 719-23
65. Peng TI, Sheu SS. Greenamyre JT. Visualization of NMDA-induced mitochondrial calcium uptake in striatal neurons using confocal microscopy. Soc Neurosci Abstr 1995 ; 21 : 1343
66. Piallat B. Benazaouz A, Benabid AL. Subthalamic nucleus lesion in rats prevents dopaminergic nigral neuron degeneration after striatal 6-OHDA injection: behavioral and immunohistochemical studies. Eur J Neurosci 1996 ; 8 : 1408-14
67. Pin JP, Duvoisin R. Neurotransmitter receptors I. The metabotropic glutamate receptors: structure and functions. Neuropharmacology 1995 ; 34 : 1-26
68. Porter RHP, Greenamyre JT. Variations in the regional pharmacology of NMDA receptor channel blockers: implications for therapeutic potential. J Neurochem 1995 ; 64 : 614-23
69. Porter RH, Greene JG, Higgins DS, Greenamyre JT. Polysynaptic regulation of glutamate receptors and mitochondrial enzyme activities in the basal ganglia of rats with unilateral dopamine depletion. J Neurosci 1994 ; 14 : 7192-9
70. Rogawski MA. Therapeutic potential of excitatory amino acid antagonists: channel blockers and 2,3-benzodiazepines. Trends Pharmacol Sci 1993 ; 14 : 325-31
71. Ramsay RR, Singer TP. Energy-dependent uptake of N-methyl-4-phenylpyridinium, the neurotoxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropiridine (MPTP). J Biol Chem 1986 ; 261 : 7585-7
72. Reynolds IJ, Hastings TG. Glutamate induces the production of reactive oxygen species in cultured forebrain neurons following NMDA receptor activation. J Neurosci 1995 ; 15 : 3318-27
73. Robledo P, Feger J. Excitatory influence of rat subthalamic nucleus to substantia nigra pars reticulata and the pallidal complex: electrophysiological data. Brain Res 1990 ; 518 : 47-54
74. Rothman SM, Olney JW. Glutamate and the pathophysiology of hypoxic-ischemic brain damage. Ann Neurol 1986 ; 19 : 105-11
75. Sawada H, Shimohama S, Tamura Y, Kawamura T, Akaike A, Kimura J. Methylphenylpyridium ion (MPP(+)) enhances glutamate-induced cytotoxicity against dopaminergic neurons in cultured rat mesencephalon. J Neurosci Res 1996 ; 43 : 55-62
76. Schapira AHV, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD. Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 1990 ; 54 : 823-7
77. Schulz JB, Matthews RT, Henshaw DR, Beal MF. Neuroprotective strategies for treatment of lesions produced by mitochondrial toxins. Implications for neurodegenerative diseases. Neuroscience 1996 ; 71 : 1043-8
78. Silverstein FS, Buchanan M, Johnston MV. Perinatal hypoxiaischemia disrupts striatal high-affinity [3H]glutamate uptake into synaptosomes. J Neurochem 1986 ; 47 : 1614-9
79. Soltis RP, Anderson LA, Walters JR, Kelland MD. A role for non-NMDA excitatory amino acid receptors in regulating the basal activity of rat globus pallidus neurons and their activation by the subthalamic nucleus. Brain Res 1994 ; 666 : 21-30
80. Storey E, Hyman BT, Jenkins B, Brouillet B, Miller JM, Rosen BR et al. 1-Methyl-4-phenylpyri-dinium produces excitotoxic lesions in rat striatum as a result of impairment of oxidative metabolism. J Neurochem 1992 ; 58 : 1975-8
81. Swerdlow RH, Parks JK, Miller SW, Tuttle JB, Trimmer PA, Sheehan JP. Origin and functional consequences of the complex I defect in Parkinson's disease. Ann Neurol 1996 ; 40 : 663-71
82. Tallaksen-Greene SJ, Albin RL. Localization of AMPA-selective excitatory amino acid receptor subunits in identified populations of striatal neurons. Neuroscience 1994 ; 61 : 509-19
83. Tallaksen-Greene SJ, Wiley RG, Albin RL. Localization of striatal excitatory amino acid binding site subtypes to striatonigral projection neurons. Brain Res 1992 ; 594 : 165-70
84. Traynelis SF, Cull-Candy SG. Proton inhibition of N-methyl-D-aspartate receptors in cerebellar neurons. Nature 1990 ; 345 : 347-50
85. Tremblay M, Salin P, Soghomonian JJ. Effect of 6-OHDA lesions on striatal mRNA levels encoding for glutamate receptor subunits. Neuroreport 1995 ; 6 : 2225-9
86. + neurotoxicity by N-methyl-D-aspartate antagonists. Nature 1991 ; 349 : 414-8
87. Tzagournissakis M, Dermon CR, Savaki HE. Functional metabolic mapping of the rat brain during unilateral electrical stimulation ot the subthalamic nucleus. J Cereb Blood Flow Metab 1994 ; 14 : 132-44
88. Ulas J, Cotman CW. Dopaminergic denervation of striatum results in elevated expression of NR2A subunit. Neuroreport 1996 ; 7 : 1789-93
89. Westbrook GL, Mayer ML. Micromolar concentrations of Zn antagonize NMDA and GABA responses of hippocampal neurons. Nature 1987 ; 328 : 640-3
90. Yamamoto BK, Cooperman MA. Differential effects of chronic antipsychotic treatment on extracellular glutamate and dopamine concentrations. J Neurosci 1994 ; 14 : 4159-66
91. Yoshino H, Nakagawa-Hattori Y, Kondo T, Mizuno Y. Mitochondrial complex I and II activities of lymphocytes and platelets in Parkinson's disease. J Neural Transm [Park Dis-Dement Sect] 1992 ; 4 : 27-34